These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17662474)

  • 21. A sensitive in-house RT-PCR genotyping system for combined detection of plasma HIV-1 and assessment of drug resistance.
    Steegen K; Demecheleer E; De Cabooter N; Nges D; Temmerman M; Ndumbe P; Mandaliya K; Plum J; Verhofstede C
    J Virol Methods; 2006 May; 133(2):137-45. PubMed ID: 16375980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of partial pol and env sequences indicates a high prevalence of HIV type 1 recombinant strains circulating in Gabon.
    Pandrea I; Robertson DL; Onanga R; Gao F; Makuwa M; Ngari P; Bedjabaga I; Roques P; Simon F; Apetrei C
    AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1103-16. PubMed ID: 12396449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations.
    Johnson JA; Li JF; Wei X; Lipscomb J; Bennett D; Brant A; Cong ME; Spira T; Shafer RW; Heneine W
    PLoS One; 2007 Jul; 2(7):e638. PubMed ID: 17653265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV type 1-infected, untreated patients in Hungary.
    Mezei M; Ay E; Koroknai A; Tóth R; Balázs A; Bakos A; Gyori Z; Bánáti F; Marschalkó M; Kárpáti S; Minárovits J
    AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1243-7. PubMed ID: 21453184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences.
    Lipscomb JT; Switzer WM; Li JF; Masciotra S; Owen SM; Johnson JA
    J Infect Dis; 2014 Dec; 210(11):1827-37. PubMed ID: 24924164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.
    Sá-Ferreira JA; Brindeiro PA; Chequer-Fernandez S; Tanuri A; Morgado MG
    Transfusion; 2007 Jan; 47(1):97-102. PubMed ID: 17207236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients.
    Charpentier C; Nora T; Tenaillon O; Clavel F; Hance AJ
    J Virol; 2006 Mar; 80(5):2472-82. PubMed ID: 16474154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
    Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.
    Kapoor A; Jones M; Shafer RW; Rhee SY; Kazanjian P; Delwart EL
    J Virol; 2004 Jul; 78(13):7112-23. PubMed ID: 15194787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations.
    Tirado G; Jove G; Kumar R; Noel RJ; Reyes E; Sepulveda G; Yamamura Y; Kumar A
    Virology; 2004 Jul; 324(2):577-86. PubMed ID: 15207642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and evaluation of an assay for HIV-1 protease and reverse transcriptase drug resistance genotyping of all major group-M subtypes.
    Aitken SC; Kliphuis A; Wallis CL; Chu ML; Fillekes Q; Barth R; Stevens W; Rinke de Wit TF; Schuurman R
    J Clin Virol; 2012 May; 54(1):21-5. PubMed ID: 22306272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
    Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
    PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi.
    Vidal N; Niyongabo T; Nduwimana J; Butel C; Ndayiragije A; Wakana J; Nduwimana M; Delaporte E; Peeters M
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):175-80. PubMed ID: 17263648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical comparison of branched DNA and reverse transcriptase-PCR and nucleic acid sequence-based amplification assay for the quantitation of circulating recombinant form_BC HIV-1 RNA in plasma.
    Pan P; Tao X; Zhang Q; Xing W; Sun X; Pei L; Jiang Y
    AIDS; 2007 Dec; 21 Suppl 8():S27-32. PubMed ID: 18172387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Primary HIV-1 drug resistance in the C-terminal domains of viral reverse transcriptase among drug-naïve patients from Southern Brazil.
    Santos AF; Silveira J; Muniz CP; Tornatore M; Góes LR; Mendoza-Sassi RA; Martinez AM; Tupinambás U; Greco DB; Soares MA
    J Clin Virol; 2011 Dec; 52(4):373-6. PubMed ID: 21975076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain.
    Lemey P; Derdelinckx I; Rambaut A; Van Laethem K; Dumont S; Vermeulen S; Van Wijngaerden E; Vandamme AM
    J Virol; 2005 Sep; 79(18):11981-9. PubMed ID: 16140774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.
    Metzner KJ; Bonhoeffer S; Fischer M; Karanicolas R; Allers K; Joos B; Weber R; Hirschel B; Kostrikis LG; Günthard HF;
    J Infect Dis; 2003 Nov; 188(10):1433-43. PubMed ID: 14624368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
    Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
    J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.